Literature DB >> 22901751

A novel function of p53: a gatekeeper of retinal detachment.

Hetian Lei1, Marc-Andre Rheaume, Jing Cui, Shizuo Mukai, David Maberley, Arif Samad, Joanne Matsubara, Andrius Kazlauskas.   

Abstract

Proliferative vitreoretinopathy (PVR) is a blinding disease associated with rhegmatogenous retinal detachment, for which there is no satisfactory treatment. Surgery helps in many cases, but, to our knowledge, there are no pharmacological approaches to reduce PVR risk. We report that suppressing expression of p53 was a required event in two assays of PVR (namely, platelet-derived growth factor receptor α-mediated contraction of cells in a collagen gel and retinal detachment in an animal model of PVR). Furthermore, preventing the decline in the level of p53 with agents such as Nutlin-3 protected from retinal detachment, which is the most vision-compromising component of PVR. Finally, Nutlin-3 may be effective in the clinical setting because it prevented human PVR vitreous-induced contraction of cells isolated from a patient PVR membrane. These studies identify Nutlin-3 as a potential PVR prophylaxis.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22901751      PMCID： PMC3432438          DOI： 10.1016/j.ajpath.2012.05.036

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


  57 in total

1.  [Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery].

Authors: 
Journal:  Arch Soc Esp Oftalmol       Date:  2000-11

2.  Akt enhances Mdm2-mediated ubiquitination and degradation of p53.

Authors:  Yoko Ogawara; Shohei Kishishita; Toshiyuki Obata; Yuko Isazawa; Toshiaki Suzuki; Keiji Tanaka; Norihisa Masuyama; Yukiko Gotoh
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

3.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.

Authors:  B P Zhou; Y Liao; W Xia; Y Zou; B Spohn; M C Hung
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

4.  Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis.

Authors:  Tanya M Gottlieb; Juan Fernando Martinez Leal; Rony Seger; Yoichi Taya; Moshe Oren
Journal:  Oncogene       Date:  2002-02-14       Impact factor: 9.867

5.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

6.  Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells.

Authors:  Christian A Wong; Michael J Potter; Jing Z Cui; Tom S Chang; Patrick Ma; Alan L Maberley; William H Ross; Valerie A White; Arif Samad; William Jia; Dan Hornan; Joanne A Matsubara
Journal:  Can J Ophthalmol       Date:  2002-06       Impact factor: 1.882

7.  An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor.

Authors:  Yasushi Ikuno; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

8.  Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery.

Authors:  Wendy Tseng; Rafael T Cortez; Gema Ramirez; Sandra Stinnett; Glenn J Jaffe
Journal:  Am J Ophthalmol       Date:  2004-06       Impact factor: 5.258

9.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

10.  mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation.

Authors:  Susan M Mendrysa; Matthew K McElwee; Jennifer Michalowski; Kathleen A O'Leary; Karen M Young; Mary Ellen Perry
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272
View more
  16 in total

1.  Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Authors:  Steven Pennock; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2014-09-26       Impact factor: 4.307

2.  Phosphoinositide 3-kinase δ inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells.

Authors:  Haote Han; Na Chen; Xionggao Huang; Bing Liu; Jingkui Tian; Hetian Lei
Journal:  J Biol Chem       Date:  2019-08-29       Impact factor: 5.157

3.  The Clustered, Regularly Interspaced, Short Palindromic Repeats-associated Endonuclease 9 (CRISPR/Cas9)-created MDM2 T309G Mutation Enhances Vitreous-induced Expression of MDM2 and Proliferation and Survival of Cells.

Authors:  Yajian Duan; Gaoen Ma; Xionggao Huang; Patricia A D'Amore; Feng Zhang; Hetian Lei
Journal:  J Biol Chem       Date:  2016-05-31       Impact factor: 5.157

4.  Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition.

Authors:  Jingjing Zhang; Gongqiang Yuan; Muchen Dong; Ting Zhang; Gao Hua; Qingjun Zhou; Weiyun Shi
Journal:  Histochem Cell Biol       Date:  2016-09-07       Impact factor: 4.304

5.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

6.  Blockade of MDM2 with inactive Cas9 prevents epithelial to mesenchymal transition in retinal pigment epithelial cells.

Authors:  Bing Liu; Jingyuan Song; Haote Han; Zhengping Hu; Na Chen; Jing Cui; Joanne Aiko Matsubara; Jingxiang Zhong; Hetian Lei
Journal:  Lab Invest       Date:  2019-08-22       Impact factor: 5.662

7.  PI3Kδ as a Novel Therapeutic Target in Pathological Angiogenesis.

Authors:  Wenyi Wu; Guohong Zhou; Haote Han; Xionggao Huang; Heng Jiang; Shizuo Mukai; Andrius Kazlauskas; Jing Cui; Joanne Aiko Matsubara; Bart Vanhaesebroeck; Xiaobo Xia; Jiantao Wang; Hetian Lei
Journal:  Diabetes       Date:  2020-01-08       Impact factor: 9.461

8.  Fibrotic remodeling of the extracellular matrix through a novel (engineered, dual-function) antibody reactive to a cryptic epitope on the N-terminal 30 kDa fragment of fibronectin.

Authors:  Maryada Sharma; Anil Tiwari; Shweta Sharma; Preeti Bhoria; Vishali Gupta; Amod Gupta; Manni Luthra-Guptasarma
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

9.  Prevention of Proliferative Vitreoretinopathy by Suppression of Phosphatidylinositol 5-Phosphate 4-Kinases.

Authors:  Gaoen Ma; Yajian Duan; Xionggao Huang; Cynthia X Qian; Yewlin Chee; Shizuo Mukai; Jing Cui; Arif Samad; Joanne Aiko Matsubara; Andrius Kazlauskas; Patricia A D'Amore; Shuyan Gu; Hetian Lei
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-07-01       Impact factor: 4.799

10.  The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy.

Authors:  Salvador Pastor-Idoate; Irene Rodríguez-Hernández; Jimena Rojas; Itziar Fernández; María T García-Gutiérrez; José M Ruiz-Moreno; Amandio Rocha-Sousa; Yashin Ramkissoon; Steven Harsum; Robert E MacLaren; David Charteris; Jan C VanMeurs; Rogelio González-Sarmiento; José C Pastor
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.